USFDA gives approval to Glenmark Pharmaceuticals for oral contraceptive
Glenmark Pharmaceuticals will be now selling the oral contraceptive -- drospirenone and ethinyl estradiol tablets, the generic version of Bayer’s yaz tablets -- in the US market. The company has recently reported to have received a final approval from USFDA.
"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing.
Glenmark said it plans to commence shipping of drospirenone and ethinyl Estradiol tablets immediately.
Citing IMS Health sales data, the company said for the 12 months period ending June, "the Yaz market achieved annual sales of approximately $170.1 million".
"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing.
Glenmark said it plans to commence shipping of drospirenone and ethinyl Estradiol tablets immediately.
Citing IMS Health sales data, the company said for the 12 months period ending June, "the Yaz market achieved annual sales of approximately $170.1 million".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.